Source: Virtual Congress 2020 – Management of chronic lung conditions
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
S. Noorduyn (Mississauga, Canada), L. Mbuagbaw (Hamilton, Canada), A. Gendron (Mississauga, Canada), M. Knutson (Mississauga, Canada), N. Sriskandarajah (Mississauga, Canada), J. Lee (Toronto, Canada). Real-world treatment patterns of mepolizumab therapy in Canada. 1680

Member's Comments

No comment yet.

Related content which might interest you: Real-world treatment patterns of benralizumab therapy for patients with severe asthma Source: Virtual Congress 2020 – Diagnosis and management of asthma Year: 2020 Real-world effectiveness and cost-effectiveness of asthma step-up options: A UK comparison of extrafine hydrofluoroalkane-beclometasone and combination therapy Source: Annual Congress 2013 –Treatment and management of asthma in primary care Year: 2013 Does adherence to ICS/LABA therapy affect response to mepolizumab in the treatment of severe asthma? Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 Severe asthma and biologic therapies during COVID-19: supporting patients care with home administration of mepolizumab and omalizumab Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies Year: 2021 The response to combination therapy treatment regimens in severe/difficult-to-treat asthma Source: Eur Respir J 2008; 32: 1237-1242 Year: 2008 Cost consequences of tiotropium plus existing therapy versus existing therapy alone following one year of treatment in patients with COPD Source: Eur Respir J 2001; 18: Suppl. 33, 5s Year: 2001 Adherence to corticosteroids and clinical outcomes in mepolizumab therapy for severe asthma Source: Eur Respir J, 55 (5) 1902259; 10.1183/13993003.02259-2019 Year: 2020 Oral glucocorticoid-sparing effects of mepolizumab. A real-life study. Source: International Congress 2018 – Innovative therapies in asthma and COPD Year: 2018 Characterising individual response to mepolizumab treatment Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma Year: 2020 Time on therapy and concomitant medication use of mepolizumab in Canada: a retrospective cohort study Source: ERJ Open Res, 7 (1) 00778-2020; 10.1183/23120541.00778-2020 Year: 2021 Safety profile of tiotropium add-on therapy in paediatric patients by gender Source: International Congress 2018 – Innovative therapies in asthma and COPD Year: 2018 Long-term treatment with fluticasone propionate/formoterol fumarate (FLUT/FORM) combination therapy is well-tolerated and provides sustained effectiveness in paediatric patients with asthma Source: Annual Congress 2011 - Treating childhood asthma Year: 2011 Cost-effectiveness of fixed-dose combinations therapies for COPD in Spain Source: International Congress 2017 – Does economisation of medicine transfer into benefits for patients? Year: 2017 Evaluation of efficacy and safety of budesonide/formeterol combination therapy in asthma patients Source: Eur Respir J 2006; 28: Suppl. 50, 314s Year: 2006 Efficacy of different dosing regimens of azithromycin in a real-world severe asthma cohort Source: Virtual Congress 2021 – Advances in asthma treatment Year: 2021 Response to mepolizumab treatment is sustained across 4-weekly dosing periods Source: ERJ Open Res, 6 (3) 00068-2020; 10.1183/23120541.00068-2020 Year: 2020 Evaluating the efficacy of chronic therapy with tiotropium in COPD through discontinuation of treatment Source: Eur Respir J 2002; 20: Suppl. 38, 245s Year: 2002 Characteristics of patients receiving mepolizumab in real-world practice –REALITI-A study Source: International Congress 2018 – New developments in the treatment of asthma Year: 2018 Economic evaluation of the impact of exacerbation frequency in COPD patients treated with single-inhaler triple therapy in Spain: The IMPACT trial Source: Virtual Congress 2020 – Pharmacological management of COPD Year: 2020 Real-world oral glucocorticoid-sparing effect of benralizumab in severe asthma Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019